Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Marksans Pharma Ltd

MARKSANS.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Small Cap Analyst: STRONG BUY

Last Close

$3.40

▲ +0.25%

Market Cap $1.54B · Vol 1.41M

Key Metrics

P/E Ratio

28.26

FWD: 26.22

Market Cap

$1.54B

Small Cap

Div Yield

0.28%

Annual dividend

EPS Growth

+26.67%

YoY

RSI (14)

55.43

Momentum

Beta

1.78

vs Market

52W High

$3.64

6.49% below

52W Low

$1.63

105.72% above

Volume

1.41M

Avg 4.46M

P/B

2.35

Price-to-book

ROE

15.22%

Return on equity

Free Float

47.51%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Marksans Pharma Ltd (MARKSANS.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MARKSANS.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.22%

+24.79%

+35.08%

+85.36%

YTD

+78.82%

+92.63%

+152.15%

+353.45%

Financials & Valuation

TTM · Annual

Total Revenue	$315.75M
Net Income	$44.95M
Revenue Growth (YoY)	+35.61%
Gross Margin	48.31%
Operating Margin	17.23%
Net Profit Margin	14.23%
ROE	15.22%
ROA · ROIC	15.79% · 14.05%

P/E Ratio	28.26
Forward P/E (FY1)	26.22
PEG Ratio	1.74
P/S	2.41
P/B	2.35
P/FCF	20.26
EPS Growth	+26.67%
Outstanding Shares	453.16M

Technical Indicators

50-Day SMA	$2.97
200-Day SMA	$2.25
RSI (14)	55.43
Beta	1.78
52-Week High	$3.64
52-Week Low	$1.63

Volume Today	1.41M
Avg Daily Volume (30D)	4.46M
Relative Volume	0.32x
Volatility (10D)	28.08
Volatility (30D)	56.38
Free Float	47.51%

Analyst Consensus

STRONG BUY

Current Price $3.40

Mean Target $3.08

52W Low$1.63 52W High$3.64

Current

Target

$1.63 $3.64

Current Analyst target

-9.28% downside risk · 2 analysts

Identifiers

ExchangeNSE India

FIGIBBG001S86217

ISININE750C01026

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Co +0.28% JNJ Johnson & Johnson +2.01% ABBV Abbvie Inc +1.39% NVS Novartis AG +6.04% NOVN.S Novartis AG +6.25%

Company Profile

Marksans Pharma Limited is an India-based company, which is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. It operates under single business segment, namely Pharmaceuticals. It operates two manufacturing facilities in Goa and maintains two research and development centers, located in Goa and in Navi Mumbai. Its product portfolio spreads various therapeutic segments of the cardiovascular system (CVS), central nervous system (CNS), antidiabetic, pain management, cough and cold, gastroenterological, and anti-allergies. Its product portfolio includes tablets (plain, enteric-coated and film-coated), hard capsules, soft gelatin capsules, oral liquids and ointments. Its consumer self-care products include pain management, upper respiratory, digestive health, vitamins, minerals and supplements (VMS) and skin care products. Its prescription - Rx therapeutic segments include CVS, CNS, oncology, anti-diabetics and anti-biotic.